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Essentials
• Zymogen PK is activated to PKa and cleaves substrates
kininogen and FXII contributing to bradykinin genera-
tion.
• Monomeric PKa and dimeric homologue FXI utilize
the N-terminal apple domains to recruit substrates.
• A high-resolution 1.3 A structure of full-length PKa
reveals an active conformation of the protease and
apple domains.
• The PKa protease and four-apple domain disc organiza-
tion is 180° rotated compared to FXI.
Summary. Background: Plasma prekallikrein (PK) and
factor XI (FXI) are apple domain-containing serine pro-
teases that when activated to PKa and FXIa cleave sub-
strates kininogen, factor XII, and factor IX, respectively,
directing plasma coagulation, bradykinin release, inflam-
mation, and thrombosis pathways. Objective: To investi-
gate the three-dimensional structure of full-length PKa
and perform a comparison with FXI. Methods: A series
of recombinant full-length PKa and FXI constructs and
variants were developed and the crystal structures deter-
mined. Results and conclusions: A 1.3 A structure of full-
length PKa reveals the protease domain positioned above
a disc-shaped assemblage of four apple domains in an
active conformation. A comparison with the homologous
FXI structure reveals the intramolecular disulfide and
structural differences in the apple 4 domain that prevents
dimer formation in PK as opposed to FXI. Two latchlike
loops (LL1 and LL2) extend from the PKa protease
domain to form interactions with the apple 1 and apple 3
domains, respectively. A major unexpected difference in
the PKa structure compared to FXI is the 180° disc rota-
tion of the apple domains relative to the protease domain.
This results in a switched configuration of the latch loops
such that LL2 interacts and buries portions of the apple 3
domain in the FXI zymogen whereas in PKa LL2 inter-
acts with the apple 1 domain. Hydrogen-deuterium
exchange mass spectrometry on plasma purified human
PK and PKa determined that regions of the apple 3
domain have increased surface exposure in PKa com-
pared to the zymogen PK, suggesting conformational
change upon activation.
Keywords: factor IX; factor XI; factor XII; kininogens;
plasma kallikrein.
Introduction
The regulation of extracellular proteolysis is critical to
blood hemostasis and innate immunity and proteases
plasma prekallikrein (PK), and coagulation factors XII
(FXII) and XI (FXI) act as master regulators of several
cascades including coagulation, fibrinolysis, complement
activation, and inflammation [1–4]. PK is an unusual
plasma protease as it does not recruit its principal sub-
strate high-molecular-weight kininogen (HK) upon activa-
tion but rather it circulates as a zymogen in a tightly
bound but inactive PK-HK complex [5], raising the ques-
tion as to how this complex is effectively regulated. The
PK zymogen can be activated by a single cleavage from
two-chain factor XIIa (FXIIa) and can also be activated
with reduced efficiency by single-chain FXII [6].
The PK-HK complex can undergo autoactivation in
the presence of zinc ions and negatively charged polymers
[7,8] including polyphosphates and nucleic acids [9].
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Prekallikrein has been shown to bind to HK via the apple
2 domain [10]. The active form plasma kallikrein (PKa)
performs a double cleavage of HK to liberate the vasoac-
tive peptide bradykinin, which binds the G-protein cou-
pled receptor (GPCR) B2R on endothelial cells leading to
activation of signaling events. Deficient regulation of the
system is exemplified by the disorder hereditary angioe-
dema where reduction of the natural inhibitor serpin C1
or a hyperactivated FXII results in excessive bradykinin
generation and recurrent attacks of severe tissue swelling
[11]. PKa is currently being targeted as a novel means to
treat diverse thrombotic [12–14] and inflammatory
disorders such as diabetic macular edema [15,16],
desquamating skin diseases, and neurodegenerative
disorders [12,17].
PK and FXI are homologous and share 58% amino
acid sequence identity with the unique feature of four tan-
dem repeats of 90 amino acid apple domains at the N-ter-
minus (Fig. 1A), which harbor exosites for substrates,
cofactors, and receptors [18]. We have previously
described the crystal structure for the inactive FXI zymo-
gen [19] and a model for the PK zymogen [20]. Factor XI
is a disulfide-linked dimer whereas PK is a monomer
[20,21]. The important active form of FXI (FXIa) has
been described as half-activated whereby one side of the
dimer remains as a zymogen with the activation loop
intact whereas the other side is cleaved [22]. In FXIa the
apple 3 domain has a binding site for the Gla domain
from substrate Factor IX (FIX) and it has been shown
that this is cryptic in the zymogen FXI [23–25]. Factor
XIIa recognizes and cleaves both PK and FXI but it is
unknown which of the apple domains is critical for these
interactions or the molecular basis of the reciprocal cleav-
age of the FXII zymogen by PKa. Here we report the
active conformation of the full-length PKa defined at high
resolution and identify large conformational and organi-
zational rearrangements compared to the structure of the
FXI zymogen.
Methods
Protein purification, crystallization, and structure
determination
A gene encoding human PK (gene KLKB1) was cloned
into the pMT-puro vector using BglII and MluI restric-
tion sites with a six-histidine tag at the N-terminus after
the immunoglobulin binding chaperone protein secretion
signal for expression using the Drosophila expression
system (Invitrogen, Carlsbad, CA, USA). A series of
constructs and mutants were evaluated to improve recom-
binant PK for crystallization purposes. The final recombi-
nant PK variant utilized site-directed mutagenesis (SDM)
(QuikChange, Agilent Technologies, santa clara, CA,
USA) to mutate two high-entropy cluster residues E323A,
K325A, K507A, and K509A, and three glycosylation sites
N377Q, N434Q, and N475Q on the catalytic domain,
together with the active site mutant S559A to prevent
autoproteolysis and optimize PK for crystallization exper-
iments (residue numbering corresponds to the mature PK
protein with signal peptide removed).
Drosophila S2 cells were grown in Dulbecco’s modified
eagle’s medium (Gibco) supplemented with 10% fetal calf
serum at 28 °C and transfection was performed using cal-
cium phosphate. Cells were grown for an additional 48 h
before selection with puromycin to establish stable cell
lines. Proteins were expressed in serum-free Express
Five insect culture medium (Gibco) and the cells were
harvested 6 days after induction with 0.5 mM CuSO4.
Protein purification was performed using a Capto S col-
umn followed by a Ni-sepharose affinity column and a
Superdex 200 gel filtration column (GE healthcare,
Boston, MA, USA).
The activated form PKa was prepared by incubating
pure recombinant PK (1 mg mL1) with b-FXIIa at a
ratio of 40 : 1 in 20 mM Tris-Cl, 150 mM NaCl, pH 8
overnight at 20 °C. The reaction was stopped by adding
benzamidine at a final concentration of 20 mM. PKa was
further purified by gel filtration (Superdex 200 column)
and then concentrated to 8.2 mg mL1. Crystallization
was performed at 20 °C and 10 °C using sparse matrix
screens (Hampton Research, Molecular Dimensions,
Qiagen, Venlo, Netherlands) in sitting drop plates. Crys-
tals were observed for PKa in the Morpheus screen with
a reservoir containing 0.1 M carboxylic acids, 0.1 M
Hepes/MOPS pH 7.5, 12.5% MPD, 12.5% PEG1000,
12.5% PEG3350 and a drop containing 0.1 M carboxylic
acids, 0.1 M Tris/BICINE pH 8.5, 20% PEG 500 MME,
10% PEG 20 000. Recombinant FXI was a gift from
Novo Nordisk and crystallized as described previously
[26]. Single crystals were transferred to the reservoir solu-
tion containing 20% glycerol, and flash cooled in liquid
nitrogen. Diffraction data were collected at Diamond
beam line I04 to 1.3 A for PKa, and the European Syn-
chrotron Radiation Facility (ESRF) beamline ID4 for the
2.6 A FXI zymogen structure. Data were processed and
reduced using XDS and the CCP4 suite [27]. The struc-
tures were determined by molecular replacement (PHA-
SER [28]) using coordinates from the FXI heavy chain
(PDB code 2F83 [19]) and PK catalytic domain (PDB
code 2ANW [29]) as search models. Models were built
with COOT [30] and refined with REFMAC. Data collec-
tion and refinement statistics are summarized in Table 1.
Figures were generated using PyMOL. A homology
model of the PK zymogen based on the FXI structure
described in Table 1 was generated using SWISSMODEL
[31], which improved the previous model [20].
Hydrogen deuterium exchange mass spectrometry
Hydrogen deuterium exchange mass spectrometry (HDX-
MS) was performed largely as described [32] on a Waters
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HDX system with nanoAcquity UPLC (Waters, Milford,
MA, USA) and Micromass Q-ToF Premier mass spec-
trometer. Samples were measured in tandem using the
same buffers to minimize the difference in back exchange.
Samples at 1.5 mg mL1 of human plasma purified PK
and PKa supplied by Enzyme Research Laboratories (ter-
med HPK and HPKa) were diluted 1 : 7 (v : v) into
labeling buffer (10 mM phosphate, 99.9% D2O, pD 7.0)
for 10 to 10 000 s at 20 °C by automated LEAP robot
pipetting. The 0-s time point was represented by the dilu-
tion into the H2O-based labeling buffer. The HDX was
quenched 1 : 1 (v : v) with precooled buffer containing
100 mM phosphate, 0.5 M TCEP, 0.8% formic acid, 2%
acetonitrile, pH 2.5 for 180 s at 1 °C and digested on a
Waters Enzymate BEH Pepsin Column (2.1 9 30 mm) at
20 lL min1. Fragments were separated on a Waters
Nano ACQUITY UPLC BEH C18 column (1.7 lm,
1.0 9 100 mm) at 40 lL min1 with a gradient of 40%
to 90% acetonitrile. Mass spectrometry was performed
using electrospray ionization in positive ion mode. Pep-
tides with no exchange were sequenced via Protein Lynx
Global Software V3.0.2, followed by amide deuterium
uptake analysis done manually via Dynamx 3.0 software.
Fragments with >0.2-Da mass deviations were removed.
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Fig 1. Structure of PKa. (A) Domain organization of plasma prekallikrein. The Arg371-Ile372 cleavage site in the activation loop is indicated.
(B) A cartoon diagram of the PKa structure shows two views related by a 90°-rotation with the protease domain in dark red and the four
apple domains colored as A1 (gray), A2 (blue), A3 (orange), and A4 (yellow). Benzamidine is shown as spheres (green) bound in the S1 pocket.
The activation loop is red with Ile372 shown as sticks salt bridging to Asp558. Interfacial residues are shown as sticks with electrostatic and
hydrogen bonds as dotted purple lines. (C) Close-up view of the interface between the PKa protease domain and apple domain disc.
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Results
Structure of full-length plasma kallikrein
To determine a full-length PKa structure recombinant
optimized PK active site mutant S559A was activated by
proteolytic cleavage of the activation loop Arg371-Ile372
using FXIIa. PKa crystallized in the presence of inhibitor
benzamidine and the structure was determined to 1.3 A
resolution (Table 1). Figure 1A shows the domain archi-
tecture and Fig. 1B the overall structure with the protease
domain positioned on top of the disc-shaped section of
the four-apple domains.
The PKa protease structure consists of two b-barrels
and the benzamidine inhibitor is observed bound in the
active site S1 pocket with the Ile372 residue from the acti-
vation loop forming the characteristic electrostatic inter-
action with Asp558 (Fig. 1B). The full-length structure
defines the interactions formed between the PKa protease
domain and the apple domains whereby two extended
loops “latch” on to the apple domains with specific inter-
actions shown in Fig. 1C. Residues 476 to 484 form a
latch loop1 and residues 566 to 570 comprise latch loop2.
The two latch loops project from the protease N-terminal
and C-terminal b-barrels, respectively, forming contacts
with residues from loops on the upper face of apple
domains 1 to 3 (Fig. 1C). Latch loop1 contains a central
b-hairpin that inserts the salt bridged residues Glu478-
Lys481 into a pocket at the center of the apple domain
disc where Glu478 forms hydrogen bonds with Arg267
and Ser90 (Fig. 1C). Latch loop1 residues Pro482, Tyr476
and the Cys364-Cys484 disulfide form a pocket that encir-
cles His87 from apple domain 1. Latch loop2 adopts an
extended b-hairpin and on its tip residue Lys566 forms a
salt bridge to Asp95 from the apple 2 domain and
Gly569 in latch loop2 forms a hydrogen bond to Gln26
from the apple 1 domain topside a-helix. Additional con-
tacts between the base of the activation loop and Arg94,
which forms a hydrogen bond to Trp380, are observed.
These three contact points encircle a central cavity
between the protease and apple domain disc that is filled
with ordered water molecules.
Comparison of the PKa apple domains with FXI
To enhance the quality of the comparison between the
two proteins and generate a more accurate model of the
PK zymogen we collected improved 2.6 A resolution
crystallographic data from crystals of the FXI zymogen
(Table 1). The higher-resolution structure revealed a
number of additional features not observed in the previ-
ously reported 3 A resolution FXI structure [19] includ-
ing definition of the activation loop residues and loops
surrounding the active site. The organization and inter-
faces between individual apple domains are closely
preserved when PKa is compared to FXI [19] with four
a-helices presented on the top surface (as viewed in
Fig. 1B) and four b-sheets on the bottom of the disc
(Fig. 2A).
An alternate conformation occurs in the apple 4
domain where an internal Cys321-Cys326 disulfide distin-
guishes PK as a monomer precluding formation of the
extensive disulfide-linked dimer interface observed in FXI
[19]. Figure 2B shows a comparison of PK (cyan) and
FXI (gray) residues 321 to 326 superposed highlighting
the intramolecular disulfide unique to PK. Figure 2C
illustrates a comparison with FXI and the altered confor-
mation of PK apple 4 domain with the internal Cys321-
Cys326 disulfide together with residues Glu319, Asp320,
both of which are not present in the FXI structure. Major
changes in the charged surface of the PK apple 4 domain
compared to the FXI apple 4 domain in the region of the
FXI dimer interface are highlighted as a dotted line in
Fig. 2D. A superposition of the FXI apple 4 domain
dimer (gray) onto the PK apple 4 domain (magenta and
cyan) illustrates steric disruption of the dimeric interface
by an altered conformation, altered charge, and a
Cys321-Cys326 disulfide bridge in the PKa structure
(Fig. 2E).
The apple 1 domains of PKa and FXI are shown on
the left and right of Fig. 2F, respectively, with the overall
conformation preserved. A thrombin binding site has
been identified in the apple 1 domain of FXI localized to
Glu66, Lys83, and Gln84 [33–35]. Factor XI Glu66 is
Table 1 Data collection and structure refinement statistics
PKa FXI
Data collection
Space group P21212 P43212
Cell dimensions
a, b, c (A) 90.6, 129.6, 55.8 80.8, 80.8, 251.1
a, b, c (°) 90, 90, 90 90, 90, 90
Wavelength (A) 0.9762 0.9334
Resolution (A) 1.3 2.6
Rmerge* 0.05 (0.682) 0.09(0.602)
I/rI 18.1 (2.5) 20.7 (2.8)
Completeness (%) 99.8 (98.0) 99.3 (96.9)
Multiplicity 6.6 (6.5) 8.8 (6.7)
CC ½ 0.999 (0.76) 0.995 (0.72)
Unique reflections 141 636 26 378
Structure refinement
Rwork 0.164 (0.253) 0.208 (0.315)
Rfree 0.196 (0.257) 0.281 (0.416)
Overall B factor (A2) 20.0 72.4
Stereochemical r.m.s.d.
Bond length (A) 0.033 0.013
Bond Angle (°) 2.82 1.77
Ramachandran statistics†
Favoured (%) 98.1 94.1
Allowed (%) 1.9 5.0
Outliers (%) 0 0.9
*The numbers in parentheses are for the highest-resolution shell.
†Ramachandran statistics are calculated using Molprobity. FXI, factor
XI; PKa, plasma kallikrein; r.m.s.d., root mean square deviation.
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Fig 2. Comparison of the PKa and FXI apple (A1–4) domains. (A) A cartoon diagram of the PKa apple 1 to 4 domain structure is shown colored
orange superposed onto the FXI apple domain structure in gray. (B) A comparison of PKa (cyan) and FXI (gray) residues 321 to 326 superposed
showing the intramolecular disulfide unique to PKa. (C) A cartoon diagram highlighting the altered conformation of PKa apple 4 domain (left),
which shows the internal Cys321-Cys326 disulfide together with residues Glu319, Asp320. These structural features are not present in FXI (right).
(D) Charged surface representation of the PKa (left) and the FXI (right) apple 4 domain showing the differences in the region of the FXI dimer
interface and the introduction of a continuous region of negative charge in PKa (dotted line). (E) Cartoon diagram showing the FXI apple 4
domain dimer (gray) superposed onto the PKa apple 4 domain (magenta and cyan) illustrating steric disruption of the interface by Cys321-Cys326.
(F) The PKa apple 1 domain (light blue on the left) is compared with the FXI apple 1 domain (gray on the right) with surface exposed residues
shown as sticks in green and disulfides in yellow. FXI residue Glu66 has been described as forming part of the thrombin binding site and this is not
conserved in PK, being replaced by Gly66 consistent with the lack of interaction between thrombin and PK. FXI, factor XI; PKa, plasma kallikrein.
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replaced by Gly66 in PKa consistent with the observa-
tions that thrombin does not interact with or activate
PK. Compared to the apple 1 domain more significant
differences occur in the region of the apple 3 domain
where a loop connecting the apple 3 and apple 4 domains
adopts alternate conformations. In FXI this connecting
loop is buried, whereas it becomes exposed onto the sur-
face generating a pocket in PKa (Fig. 3A–C). The largest
difference is observed for residues 266 and 267, which are
buried in the center of the apple domain disc in FXI (pur-
ple in Fig. 3D) but are presented on the surface in PKa
where Lys266 and Arg267 combine to form a positively
charged patch (Fig. 3B). In the comparison of PKa and
FXI the apple 3 domain Cys182-Cys265 disulfide switches
its side chain rotamers significantly to accommodate this
conformation change whereas in the apple 1 domain the
equivalent Cys2-Cys85 disulfide remains in one conforma-
tion (Fig. 2F).
Figure 3D highlights the apple 1 domain is equivalent
to the apple 3 domain in terms of the way the domains
are arranged in the disc as the long a-helix is partially
buried between the interdomain loops and is tucked clo-
ser to the center of the apple domain disc whereas the
equivalent a-helix in the apple 2 and apple 4 domains is
located radially on the surface. This disposition means
both the apple 1 and apple 3 domains present two equiva-
lent solvent exposed surfaces labeled surface 1 and 2 in
Fig. 3B. In FXI residues from surface 1 have been identi-
fied as the apple 3 domain binding site for the substrate
FIX Gla domain [25,36,37] and surface 2 is the location
of the FXI anion binding site whereas the function of
these surfaces is unknown in PK [23].
T210
R267
K266
M184
F206
R267
H267
R266 PKa/
FXI
PKa/
FXI
A4
A3
A2
FXI R266-H267 PK K266-R267
A1
FXI
A3-A4 loop
buried
K266
PKa
A3-A4 loop
exposed
C182-C265
disulfide
K277 basic patch Surface 1
Surface 2
PKa
A3
A3-A4 loopA
C
D
B
Fig 3. Comparison of the PKa and FXI apple 3 domains. (A) A cartoon diagram of the PKa apple 3 domain structure is shown with key resi-
dues highlighted as sticks. (B) Charged representation of the apple 3 domain upper surfaces. A pocket formed by the loop connecting to the
apple 4 domain is indicated by a dashed elliptical line labeled as surface 1. A second flat surface 2 is defined by residues from the N-terminal
region of the apple 3 domain. (C) Cartoon diagram showing a superposition of the loop structure connecting the apple 3 and 4 domains from
PKa with the equivalent FXI structure. Residues Lys266 and Arg267 (green) from PKa are raised and become surface exposed compared to
the equivalent residues His267 and Arg266 in FXI (purple), which are buried. Disulfides are in yellow. (D) Cartoon diagram showing the PKa
and FXI apple 1 to 4 domains superposed and colored as in Fig. 1. Key residues showing a major conformational difference in the apple 3 to
4 domain connecting loop are shown as sticks. FXI, factor XI; PKa, plasma kallikrein.
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Fig 4. Comparison of full-length PKa and FXI zymogen structures. (A) A schematic diagram of the domain organization observed in the FXI
zymogen monomer (left) with two latch loops (LL1, LL2) located above the apple 3 domain compared to the PKa structure (right) with the
latch loop 1 interacting with the apple 1 domain. (B) Cartoon diagram of the FXI zymogen crystal structure protease domain above a surface
representation of the apple domains and (C) PKa with an equivalent orientation of the protease domain and color scheme to illustrate the large
180° relative rotation of the apple domains. The latch loops are pink and the activation loop red. (D) The FXI apple domains alone are shown
as a surface representation with latch loop1 and loop2 (pink) and the activation loop (red) shown as cartoon. (E) The same figure of PKa
shows the positions of the three loops at the interface between the protease domain illustrating 180°-rotation compared to FXI with the latch
removed and partially disordered (dotted line). Close-up views of the latch loops “on” in FXI are shown in (F) with an equivalent latch loop
orientation shown for PKa in (G). Key residues are highlighted as sticks including the Asp488 from latch loop 1, which covers the substrate
binding pocket in the FXI zymogen. FXI, factor XI; PKa, plasma kallikrein.
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Differences in the overall organization of PKa compared to
FXI
A comparison of the full-length structures of PKa with the
FXI zymogen revealed a large unexpected conformational
180° rotational rearrangement of the intact apple domain
disc relative to the protease domain (Fig. 4A–C). The PKa
latch loop1 is a key pivot point for this relative rotation as
it contains the Cys364-Cys484 disulfide which anchors the
protease domain to the apple domains after cleavage of
the Arg371-Ile373 peptide bond in the activation loop. A
comparison between the FXI and PKa latch loop1 struc-
ture reveals the PKa b-hairpin Glu478-Lys481 ion pair is
conserved as Asp476-Arg479 in FXI. Latch loop1 has a
180° relative rotation from its position above the apple 3
and 4 domains in FXI where Asp476 interacts with
Arg369 from the activation loop closer to the center of the
disc inserting into a central pocket of PKa (Fig. 4B–E).
Latch loop2 maintains a similar extended b-hairpin struc-
ture in both PKa and FXI but whereas in FXI the interac-
tion is with the apple 3 domain in PKa this equivalent b-
hairpin has moved by 40 A to form interactions with the
topside a-helix of the PKa apple 1 domain (Fig. 4F,G).
Large relative rotational changes in the position of
latch loop1 and 2 are consistent with previous biochemi-
cal data that FXI residues Asp488 and Asn566 act as a
latch in the FXI zymogen structure covering the substrate
factor IX (FIX) binding pocket in the apple 3 domain
[24] (Fig. 4F). In the PKa structure, residues 488 to 493
containing the homologous region of the FXI latch are
not observed in the PKa electron density and are assumed
to be disordered and flexible, labeled as “latch off” in
Fig. 4E,G. It is interesting to observe the direct interac-
tions between the FXI activation loop residue Arg369
and the latch loop1 Asp476 (Fig. 4D,F).
Hydrogen deuterium exchange protection differences
between PK and PKa
To investigate whether large conformational differences
exist between the PK zymogen and PKa in solution,
HDX-MS was performed on human plasma purified sam-
ples (termed HPK and HPKa). With this approach, the
extent of deuterium exchange of backbone amide protons
in HPK and HPKa was evaluated as a function of time.
For HPK, 150 peptide fragments were assigned, achieving
94.9% sequence coverage and a redundancy of 4.99. For
HPKa, 113 peptide fragments were assigned, achieving
94.7% sequence coverage and a redundancy of 3.14. Heat
maps showing relative fractional deuterium uptake over
exchange time were calculated with Dynamx Software. A
residual heat map of each HPK and HPKa fragment from
0 to 10 000s is shown in rainbow scale (Fig. 5A), accom-
panied by the corresponding peptide coverage map below.
Residues with no peptide coverage are left blank. Fig-
ure 5B shows the examples of deuterium uptake for some
identical peptides in HPK and HPKa, with significant dif-
ferences in deuterium uptake observed for residues 181 to
193 and 267 to 277, implying that these residues on the
upper surface of the apple 3 domain are more exposed in
HPKa compared to HPK. In addition, example peptides
are shown that have little difference between HPK and
HPKa such as peptide 111 to 121. These regions appear
structurally congruent between the PK zymogen model
and PKa structure. The complete set of deuterium uptake
plots for all the assigned peptides in HPK and HPKa is
included as Figs. S1 and S2.
Solvent accessibility differences between the PK zymo-
gen model and PKa structure were calculated using the
program STRIDE [38] and overall, the HDX-MS results
are consistent with the accessibility data. Notably, a sig-
nificant change occurs for residues 267 to 277 in the loop
connecting the apple 3 and apple 4 domain, which is
folded toward the center of the apple domain disc and
buried by the protease domain in the PK zymogen com-
pared to PKa where a radically different conformation of
this loop exposes residues 262 to 268 onto the surface of
the disk adjacent to residues 180 to 185, which also show
an increase in accessibility (Fig. 5C). A 3D projection of
HDX data at the 10 000 s exchange time mapped to the
structure of PKa and the PK zymogen model apple 3
domain is shown in Fig. 5D,E. Thus the HDX data sup-
port a model whereby the apple 3 domain top surface
residues become exposed when PK is activated to PKa.
The heat map reveals differences in the region around
residue 75 in the apple 1 domain that are more surface
exposed in HPKa compared to HPK. This region is not
predicted to have changes in surface exposure from the
structural comparison of PKa with the PK model and
may reflect the reduced peptide coverage in this region
compared to the apple 3 domain or an incomplete
description of the PK model.
Fig 5. Hydrogen-deuterium exchange (HDX) characterization of PK and PKa. (A) Heatmaps showing relative fractional uptake over exposure
time via Dynamx Software. For PK, 150 peptide fragments were assigned, achieving 94.9% sequence coverage and a redundancy of 4.99. For
PKa, 113 peptide fragments were assigned, achieving 94.7% sequence coverage and a redundancy of 3.14. (B) Deuterium uptake of specific
peptides in PK and PKa. Deuterium uptake for peptides shared between the data sets was plotted over time of D2O exposure. Structural differ-
ences at the rotation site are consistent with HDX data presented, while structural consistencies remain largely the same and are supported in
the HDX data. (C) Mass spectra of highlighted peptides that show differences in the PK and PKa apple 3 domain from 0 to 10 000 s D2O
exposure. (D) Cartoon diagram of the PKa apple 3 domain crystal structure showing greater deuterium exchange for residues in the region of
residues 180 to 185 (light blue) and 262 to 270 (green/yellow colored based on the heatmap) compared to (E) the PK zymogen apple 3 domain
model with reduced deuterium exchange for the equivalent regions (dark blue). FXI, factor XI; PKa, plasma kallikrein.
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Discussion
We present the first example of a full-length crystal struc-
ture for PKa at 1.3 A resolution, which defines the
detailed organization of the active protease domain and
its relationship to the four ancillary apple domains. A
comparison with a 2.6-A FXI zymogen structure revealed
significant conformational differences in the apple 4
domain defining the molecular basis of the monomeric
PKa structure versus the FXI dimer. A major conforma-
tional difference is also observed in the apple 3 domain
with residues from the loop connecting the apple 3 to the
apple 4 domain becoming exposed in PKa as opposed to
being buried in the center of the apple domain disc in the
zymogen form of FXI. It is tempting to speculate that
PK may undergo conformational rearrangements upon
activation based on the comparison of the FXI and PKa
structures. This hypothesis is supported by HDX mass
spectrometry measurements on plasma purified human
PK and PKa determining that regions of the apple 3
domain have increased surface exposure in PKa com-
pared to the zymogen PK. The biological significance of
the increased exposure of residues on the upper surface of
the apple 3 domain is unknown for PK but has been pro-
posed to occur in FXI to regulate substrate binding
[21,24]. Here it was shown that FXIa has an exosite for
the FIX Gla domain involving residues 183 to 185 from
the FXIa apple 3 domain, which is cryptic in the FXI
zymogen [25,36,37]. Consistent with this the FXI zymo-
gen structure shows Arg184 is buried and forms a salt
bridge with Asp488 from the catalytic domain (LL1), ren-
dering it unavailable for binding to the FIX Gla domain
[19,21]. By comparison with the apple 3 domain the
apple 1 domain does not experience a large change in
conformation.
A comparison of PKa with the FXI structure revealed
a large conformational 180° rotational rearrangement of
the intact apple domain disc relative to the protease
domain. Low-resolution structural studies and biochemi-
cal data comparing the homologous FXI and active form
FXIa have suggested that a large conformational shape
change occurs upon activation [39,40]. Future studies will
be required to determine a crystal structure of the PK
zymogen to establish whether this mirrors the conforma-
tion observed for the FXI zymogen and to determine
whether the PKa apple 3 domain is utilized for substrate
recruitment as it is in FXIa. Other substrates reported for
PKa include the integral membrane proteins protease
activated receptor (PAR), PAR-1, and PAR-2 implicated
in regulation of blood-brain barrier integrity [41] and pla-
telet activation [42]. It is interesting to note that the P1-
P10 cleavage site Arg-Ser in the PAR-1 and PAR-2
sequences also occurs in the classical PKa substrate HK
to release bradykinin [43]. The cleavage of extracellular
matrix proteins by PKa has also been described in the
astrocyte secretome although the precise location of the
cleavage sites and involvement of the apple domains in
substrate selection remains unknown [44]. The interaction
of PK and FXI with cell receptors has been characterized
and the apple domains have been reported to be impli-
cated although the precise binding sites remain unknown
[21,45].
Overall these new structures provide the first insight
into the active conformation of the apple domain contain-
ing protease PKa and generate a scaffold for development
of future medicines targeting PKa in diverse inflamma-
tory, thrombotic, and vascular disorders [12,13].
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